Video

The Impact of PCSK9 Inhibitors on Specialty Pharmacy

Author(s):

Lauren Santye, Assistant Editor

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Gang | stock.adobe.com
Related Content
High-density lipoprotein particles(HDL) also known as good cholesterol, in the blood. Higher HDL levels correlate with lower risk of cardiovascular disease
August 24th 2025

Elevated High-Density Lipoprotein Cholesterol May Reduce Risk of Stress Urinary Incontinence

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
August 24th 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Diagnosis papers for chronic kidney disease (CKD) -- Image credit: Dzmitry | stock.adobe.com
August 24th 2025

UNI-494 Receives US Patent for Treatment of Chronic Kidney Disease

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
August 24th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Treatment for chronic kidney disease (CKD) -- Image credit: jarun011 | stock.adobe.com
August 24th 2025

Study Finds Biomarkers That May Help Predict, Manage Chronic Kidney Disease

Gillian McGovern, Associate Editor
Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment
August 24th 2025

Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment

Amy C. Nieto, BS, PharmD Candidate